Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
2.
Cutan Ocul Toxicol ; 39(2): 171, 2020 06.
Artículo en Inglés | MEDLINE | ID: mdl-32183543

RESUMEN

We read Cosansu's commentary entitled "Effectiveness of the new inflammatory parameters in patients with chronic spontaneous urticarial" to our study with great interest. The author remarked that a limited number of patients had C-reactive protein levels and it was not specified whether there were any other drugs used by the patients and no information was given about the severity of the disease in our study.


Asunto(s)
Antialérgicos , Urticaria , Antialérgicos/uso terapéutico , Enfermedad Crónica , Humanos , Omalizumab/uso terapéutico , Urticaria/tratamiento farmacológico
3.
Cutan Ocul Toxicol ; 38(1): 5-8, 2019 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-29969297

RESUMEN

PURPOSE: The mechanism of action of omalizumab in chronic spontaneous urticaria (CSU) is not exactly known. In previous studies, d-dimer which is a fibrin-degradation product and interleukin-31 which has a role in inflammation were found to be decreased in patients with chronic urticaria treated with omalizumab. However, to our knowledge, there is no study on the effects of omalizumab on the ratio of neutrophil to lymphocyte (NLR) and the ratio of platelet to lymphocyte (PLR) which are inflammatory parameters in patients with CSU in the PubMed database. In this study, we aimed to evaluate the effects of omalizumab on hematological and inflammatory parameters in patients with CSU. MATERIALS AND METHODS: One hundred six CSU patients treated with omalizumab were evaluated retrospectively. Complete blood count (CBC) and C-reactive protein (CRP) levels before treatment and at the third month of treatment were recorded. NLR and PLR were calculated from the CBC results. CBC parameters, CRP levels, NLR and PLR of the patients before treatment and at the end of third month of treatment were compared. RESULTS: There was a significant decrease in white blood cell count, platelet count, neutrophil count, CRP level, NLR and PLR and a significant increase in mean platelet volume and eosinophil count with omalizumab treatment in CSU patients (p < 0.05). Basophil count increased; but there was no statistically significant difference (p = 0.293). CONCLUSION: This study shows that omalizumab has not only anti Ig E effect, but also it may have inhibitory effects on inflammation and coagulation in patients with CSU. Further prospective studies are warranted in order to evaluate the effect of omalizumab on hematological and inflammatory parameters and correlation between omalizumab response rate and these inflammatory parameters in patients with CSU.


Asunto(s)
Antialérgicos/uso terapéutico , Antiinflamatorios/uso terapéutico , Omalizumab/uso terapéutico , Urticaria/tratamiento farmacológico , Adulto , Recuento de Células Sanguíneas , Proteína C-Reactiva/análisis , Femenino , Humanos , Masculino , Persona de Mediana Edad , Urticaria/sangre
4.
Ann Dermatol ; 31(4): 372-377, 2019 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-33911614

RESUMEN

BACKGROUND: Anxiety sensitivity (AS) is a continuous fundamental fear and defined as extreme fear of anxiety sensations and symptoms. High AS can cause tendency to anxiety disorders. There are many studies evaluating the anxiety in patients with acne; however, AS has not been investigated. OBJECTIVE: We aimed to investigate AS in patients with acne. METHODS: Two hundred and fourteen acne patients and 117 healthy control subjects, aged older than 16 years were enrolled in the study. Severity of acne was evaluated by Global Acne Grading System. The acne patients and healthy controls were asked to complete the anxiety sensitivity index-3 (ASI-3), the Beck anxiety inventory (BAI) and the Turkish version of acne quality of life index. RESULTS: Anxiety and AS levels in acne patients were significantly higher than healthy controls (p<0.001). Quality of life was impaired in acne patients. Quality of life was negatively correlated with anxiety and AS levels in acne patients (p=0.014, p=0.019, respectively). There was no correlation between quality of life and disease severity (p=0.556) and also there was no correlation between psychiatric scale scores (ASI-3, BAI) and disease severity (p=0.147, p=0.871, respectively). CONCLUSION: To our knowledge, our study is the first to report that AS is high in acne patients. Clinically, our results suggest that there might be a relationship between AS and acne. We conclude that further studies are needed in order to clarify the relationship between acne and AS and to investigate the efficacy of cognitive behavioral treatments in acne patients.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...